AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06607185
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06607185
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT05340504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
Trial: NCT06075953
Drug: Testosterone + Anastrazole
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Trial: NCT05491733
Drug: APX001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-load oral tablet
Trial: NCT05491733
Drug: APX001A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-load oral tablet
Trial: NCT04964258
Drug: TAK-105-a Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-105-a placebo-matching solution.
Trial: NCT04791943
Drug: Melatonin 10 MG
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 melatonin 10mg capsules will be given to the treatment arm
Trial: NCT04791943
Drug: Lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 lactose pills will be provided to the control arm
Trial: NCT06002152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
Trial: NCT05409417
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
Trial: NCT05021809
Drug: Calcium hydroxide intracanal medication application
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
Trial: NCT06671002
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses
Trial: NCT06671002
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
Trial: NCT06671002
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
Trial: NCT06672900
Drug: ALG-000184
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Investigational Product
Trial: NCT06432127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
Trial: NCT06598397
Drug: Combination NRT
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
Trial: NCT00246168
Drug: tramadol hydrochloride + acetaminophen
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00365755
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05232734
Drug: Caffeine Citrate 20 MG/ML Oral Solution
RxNorm normalized name: Caffeine citrate 20 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
Trial: NCT06656416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet BID
Trial: NCT06656962
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
Trial: NCT06656091
Drug: simmitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simmitinib 6mg,QD ,3 weeks on 1 week off
Trial: NCT05439616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules or Oral Solution
Trial: NCT05516914
Drug: LBL-007 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose - MTD; Q3W; intravenous infusion
Trial: NCT04892563
Drug: IV Analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesia, typically Morphine/Opioid medications
Trial: NCT06151925
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin for ripening
Trial: NCT05041166
Drug: Hyperpolarized [13C] Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
Trial: NCT05135364
Drug: TKI
RxNorm normalized name: Catkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib or Regorafenib
Trial: NCT05250856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, (0.9% Sodium Chloride for IV infusion)
Trial: NCT06462716
Drug: BY101298 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral DNA-PK Inhibitor
Trial: NCT05181605
Drug: Folfirinox and Stereotactic Body Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
Trial: NCT01606982
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05169671
Drug: ATH-1020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATH-1020 in oral capsule form
Trial: NCT05169671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in oral capsule form
Trial: NCT05418712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-150 for oral administration.
Trial: NCT06231043
Drug: Diclofenac/Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
Trial: NCT05005884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of oral phenolics 250 mg two times daily
Trial: NCT04095858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 100 ml at Day -1, Day 14, and Day 28.
Trial: NCT04095858
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
Trial: NCT04702074
Drug: Traditional Chinese medicine granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months.
Trial: NCT04702074
Drug: Traditional Chinese medicine granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules .
Trial: NCT05450289
Drug: Nigella Sativa Oil
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
Trial: NCT05450289
Drug: Standard pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
Trial: NCT06663995
Drug: Study Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy
Trial: NCT06663995
Drug: Control (placebo) group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
Trial: NCT05036083
Drug: Iodinated Contrast Agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06131918
Drug: Super Oxide Dismutase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Trial: NCT06583083
Drug: P-GEMOX Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Trial: NCT01969656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04972760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 mg/d, oral route for 24 weeks
Trial: NCT05779163
Drug: LBL-033 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose - MTD; Q2W; intravenous infusion
Trial: NCT06671041
Drug: Preservative Free eye drop
RxNorm normalized name: GenTeal Tears Moderate Lubricant Preservative Free Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were required to use a lubricating eye drop
Trial: NCT05668741
Drug: VX-522 mRNA therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral inhalation using nebulizer.
Trial: NCT05658380
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
Trial: NCT05363917
Drug: Natrunix with MTX placebo (+folate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
Trial: NCT05363917
Drug: Natrunix placebo with MTX (+folate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natrunix placebo with MTX (+folate)
Trial: NCT04828824
Drug: Ethinyl Estradiol / Norgestimate Oral Tablet
RxNorm normalized name: ethinyl estradiol / norgestimate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
Trial: NCT06672445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by IT administration
Trial: NCT06616194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral disintegrating tablets
Trial: NCT05334329
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05475678
Drug: TCb regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel + carboplatin regimen
Trial: NCT06172894
Drug: APN401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
Trial: NCT06468371
Drug: Dopamine Agonist (Ropinirole)
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
Trial: NCT06608992
Drug: SURGICEL® Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
Trial: NCT06388824
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
Trial: NCT03561376
Drug: Topical zinc oxide vs. petrolatum post-surgical scars
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery.
Trial: NCT04724928
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
Trial: NCT06657300
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
Trial: NCT05740007
Drug: IW-3300 rectal foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-3300 rectal foam administered daily for 12 weeks
Trial: NCT05740007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rectal foam administered daily for 12 weeks
Trial: NCT05890105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
Trial: NCT06479603
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
Trial: NCT04561180
Drug: EG-009A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an Intramuscular injection
Trial: NCT04561180
Drug: EG-009A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an Intramuscular injection
Trial: NCT05134857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
Trial: NCT06084806
Drug: [18F]F-ARAG PET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two imaging sessions
Trial: NCT06543992
Drug: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
Trial: NCT06494878
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Trial: NCT06746753
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized to receive Norepinephrine continuous infusion for up to 48 hours
Trial: NCT06747247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appear similar to MT1013, but has no treatment effect.
Trial: NCT06607029
Drug: the opioid-based control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
Trial: NCT05383820
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Trial: NCT05127486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05127486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05988814
Drug: FOLFIRINOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression
Trial: NCT05402384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo